Regulatory Affairs Committee

Chairman: Kamma Hansen, Alternova

The Regulatory Affairs Committee will promote regulatory interests for the IGL board by:

• Monitoring and commenting on relevant domestic drug legislation
• Monitoring and commenting on relevant EU drug legislation
• Keeping up-to-date and commenting on the Danish Medicines Agency’s performance
• Representing IGL in the EGA’s regulatory committee (RSAC-Regulatory and Scientific Affairs Commitee) 
• Establishing relevant interest groups as needed